contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


prolight-announces-timetable-for-share-reverse-split

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Prolight Diagnostics develops point-of-care (POC) systems. These are small mobile instruments with disposable test cards that can perform In-Vitro Diagnostic (IVD) tests from a drop of blood. The POC system can contribute to faster and more accurate diagnoses of acute conditions. The company's launch product will be a highly sensitive measurement of troponin to be able to determine and exclude heart attacks.

Prolight Diagnostics

The extraordinary general meeting in Prolight Diagnostics AB (publ) on 19 November 2025, resolved on a reverse share split of 1:100, whereby one hundred (100) existing shares will be consolidated...

<div class="mfn-body"><p><strong>The extraordinary general meeting in Prolight Diagnostics AB (publ) on 19 November 2025, resolved on a reverse share split of 1:100, whereby one hundred (100) existing shares will be consolidated into one (1) new share. The extraordinary general meeting authorised the board of directors to determine the record date for the reverse share split. The board of directors has, pursuant to the authorisation, resolved that the record date for the reverse share split shall be 11 December 2025.</strong></p><p>Timeline for the reverse share split:</p><table><tbody><tr><td valign="middle" rowspan="1" colspan="1" align="justify">9 December 2025</td><td valign="middle" rowspan="1" colspan="1" align="justify">The last day of trading in Prolight’s shares before the reverse share split.</td></tr><tr><td valign="middle" rowspan="1" colspan="1">10 December 2025</td><td valign="middle" rowspan="1" colspan="1" align="justify">First day of trading in Prolight’s shares following the reverse share split. From this date, the share price will reflect the effect of the reverse share split.</td></tr><tr><td valign="middle" rowspan="1" colspan="1" align="justify">11 December 2025</td><td valign="middle" rowspan="1" colspan="1" align="justify">Record date for the reverse share split</td></tr></tbody></table><p>Shareholders are not required to take any action to participate in the reverse share split. Following the reverse share split, Prolight’s shares will change ISIN code. The new ISIN code SE0027099656 will apply from 10 December 2025.</p><p>A shareholder who on the record date does not hold a number of shares that is evenly divisible by 100 will receive, from Mangold Fondkommission AB (the guarantor), free of charge such number of shares (1–99 shares) that the shareholder's holding, after addition of provided shares, is evenly divisible by 100 (so-called rounding up). The provision of such equalization shares will be provided through Euroclear Sweden AB, without requiring any further action from shareholders.<br>Following the reverse share split, the number of shares in the company will amount to 12,044,782, which represents a quota value of SEK 10 per share.</p></div><div class="mfn-footer mfn-contacts mfn-de1edede6694"><p><strong class="mfn-heading-1">For further information, please contact:</strong><br>Ulf Bladin, CEO<br>E-mail: <a rel="noopener" href="mailto:info@prolightdx.com">info@prolightdx.com</a><br>Phone: +46 73 582 39 87<br>Company website: <a rel="noopener" href="http://www.prolightdx.com">www.prolightdx.com</a></p></div><div class="mfn-footer mfn-about mfn-59c4de0219f5"><p><strong class="mfn-heading-1">About Us</strong><br>Prolight Diagnostics AB develops innovative Point-of-Care systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood. We want to offer the foremost POC systems on the market for quick, reliable diagnosis of acute events. Our launch product will be for the measurement of high sensitive troponin, to aid in the rule-in and rule-out of myocardial infarction.<br>&nbsp;<br>The company’s share is traded on the NGM Nordic SME marketplace, under the ticker PRLD.</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/1dc4f857-f879-4ada-858f-330a3eed0a11/prolight-announces-timetable-for-share-reverse-split.pdf" class="mfn-generated mfn-primary">Prolight announces timetable for share reverse split</a></p></div>

9 December 2025	The last day of trading in Prolight’s shares before the reverse share split.
10 December 2025	First day of trading in Prolight’s shares following the reverse share split. From this date, the share price will reflect the effect of the reverse share split.
11 December 2025	Record date for the reverse share split